efforts aimed at HAI prevention. Interest in HAI surveillance data has recently expanded beyond the infection control community. The HAI rates, for example, are currently publicly reported in many locales to facilitate comparisons among medical facilities and to promote improvements in processes and outcomes. These data will have increasing impact on hospital reimbursement in the United States from major payers, including the Centers for Medicare and Medicaid Services. As of October 2008, hospitals no longer receive additional payment from Centers for Medicare and Medicaid Services for mediastinitis after coronary artery bypass graft surgery or for SSIs after specific orthopedic procedures and bariatric surgery [1] [2] [3] . Of consequence, it is increasingly important to hospitals, payers, and health care consumers that data on HAIs be accurate, complete, risk stratified, and comparable among institutions.
Most infection prevention programs in US hospitals use SSI definitions established by the Centers for Disease Control and Prevention's (CDC's) National Nosocomial Infection Surveillance system (now the National Healthcare Safety Network [NHSN] ). Although definitions of SSI are standardized, methods for case finding and data sources used for surveillance vary substantially among institutions. In addition, conventional SSI surveillance requires time-intensive medical record review by trained infection preventionists and is subject to interobserver variability. Hospitals' increasing infection prevention responsibilities underscore the need for efficient and accurate surveillance methods. These limitations of conventional surveillance have led to the development of alternative surveillance strategies that use electronic health data [4] [5] [6] [7] [8] [9] [10] [11] .
Yokoe et al. [12] reported superior case finding with use of automated data from administrative and pharmacy databases to identify SSIs in patients undergoing coronary artery bypass graft surgery, cesarean delivery, and breast operations. By increasing the sensitivity for detecting SSIs and, thus, providing a more accurate picture of hospitals' SSI burden, this method may improve the efficiency of the surveillance process by eliminating the need for medical record review for a large proportion of patients who are unlikely to have developed an SSI. The goal of the current study was to validate this method after total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures. We chose these procedures because they are frequently performed in the United States and are targeted in the Surgical Care Improvement Project, a collaborative SSI prevention effort led by the Centers for Medicare and Medicaid Services, the Joint Commission, the CDC, and other organizations focused on quality improvement.
PATIENTS AND METHODS
We conducted 2 parallel studies at 8 hospitals affiliated with 6 CDC Prevention Epicenters that evaluate the use of quantitative antimicrobial exposure and diagnosis codes to detect SSIs after THA and TKA procedures. The CDC Prevention Epicenters are a collaborative research network funded by the CDC. The same study design was used for evaluation of both surgical procedures. The study received institutional review board approval at each study site. Because of institutional review board restrictions, 1 institution excluded cases that occurred in prisoners.
Study design and study population. We conducted a retrospective cohort study that involved patients aged у18 years who underwent THA at 4 medical centers from 1 July 2002 through 30 June 2004, and TKA at 5 medical centers from 1 July 2003 through 30 June 2005. Infection preventionists at these centers used NHSN surveillance definitions to perform routine, prospective SSI surveillance after THA and TKA, including superficial incisional SSIs that occurred within 30 days after the original surgery and deep incisional and organ/space SSIs that occurred up to 1 year after the original surgery. Patients were included in our study if they had been assigned an International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code for THA (81.51 or 81.52) or TKA (81.54) during the study periods. Patients who had undergone revision arthroplasty were excluded. Research personnel retrospectively reviewed the medical records of all patients who had been classified as having an SSI through routine surveillance. In addition, research personnel reviewed medical records of a random sample of ∼200 patients without a known SSI who underwent study procedures at each center.
Data collection. Medical record review at all sites was limited to inpatient medical records. Patient records were retrospectively reviewed for clinical evidence of SSIs (based on NHSN criteria) during the initial hospitalization for surgery (hereafter referred to as the index hospitalization) and any subsequent hospitalizations in the same hospital within the 365 days after the procedure. Any SSIs identified solely in the outpatient setting were excluded. In addition, records were reviewed for the presence or absence of specific ICD-9-CM diagnosis codes indicative of postoperative infection (998.5, 998.51, or 998.59) or prosthetic joint infection (996.66) for the index hospitalization or any subsequent hospitalizations within 365 days after the procedure.
Pharmacy data regarding intravenous or oral antimicrobial therapy administered postoperatively during the index hospitalization or during any subsequent hospitalization within the 365 days after the procedure were extracted. Antimicrobial exposure intervals were calculated as the number of days from the first day through the final day of antimicrobial use, excluding the day of surgery and the first postoperative day to omit antimicrobials administered for perioperative prophylaxis. Patients did not need to receive antimicrobial agents on each day or the same agent throughout the interval. For example, a patient who received cefazolin on postoperative day 3, no antimicrobials on days 4-10, and an oral fluoroquinolone on day 11 was considered to have an antimicrobial exposure interval of 9 days. We also identified patients who received any oral or parenteral antimicrobial therapy during a subsequent hospitalization in the same hospital within 365 days after the operative procedure. Antiviral and antifungal agents were excluded.
At the onset of the study, each site validated their data collection methods by having 2 reviewers perform medical reviews of 10% of the intended sample. All centers were required to achieve k scores of у0.60 before proceeding with additional data collection. All data were submitted to the coordinating institution for analysis. Data were entered into a Microsoft Office Access form. Data analysis. The total number of SSIs that were not detected through routine surveillance was estimated by multiplying the SSI rate identified by medical record review of the random sample of patients not known to have SSIs based on routine surveillance by the number of patients in the entire cohort who were not known to have SSIs. This estimate was added to the number of SSIs identified through routine surveillance to calculate an adjusted SSI rate.
The optimal antimicrobial exposure threshold was determined by dividing the data into a training and a validation set. The threshold antimicrobial interval with the best combination of sensitivity and specificity when fit to a receiver operating characteristic curve was identified using the training set data and was confirmed using the validation set. The sensitivity and positive predictive value (PPV) of routine prospective surveillance, screening based on antimicrobial exposure, diagnosis codes, and combinations of these were estimated using the sampling fractions to extrapolate to the source population.
Clinical features of patients with and without SSIs were compared using Fisher's exact test or the Wilcoxon rank sum test, when appropriate. All tests were 2-tailed with statistical significance set at . Statistical testing was performed using P p .05 SAS statistical software, version 9.1 (SAS Institute).
RESULTS

THA.
During the study period, 2128 THA procedures were performed at the 4 participating medical centers (range, 62-927 procedures per hospital). Sixteen SSIs (0.75%) were detected by routine surveillance, including 7 superficial incisional, 7 deep incisional, and 2 organ/space SSIs. Retrospective medical record review of medical records for the random sample of 680 patients who were not previously known to have SSIs identified 4 additional SSIs (1 superficial incisional SSI, 2 deep incisional SSIs, and 1 organ/space SSI). Extrapolating to the entire study population, the adjusted overall SSI rate was 1.32%. Ninety percent of the SSIs were detected during subsequent hospitalizations rather than during the index hospitalization (table 1 ). An antimicrobial exposure threshold of у7 days during the index hospitalization had the best combination of sensitivity and specificity for detecting SSIs. The ICD-9-CM diagnosis codes suggestive of SSIs were assigned infrequently during the index hospitalizations and were not useful for discriminating between patients with SSIs and those without SSIs.
Readmission to the hospital during the 365 days after the surgical procedure was significantly more common among the patients with SSIs. The time to hospital readmission was significantly shorter for persons with SSIs (median, 20 days; interquartile range, 22 days) than for patients who were readmitted for other reasons (median, 116 days; interquartile range, 184 days) (table 1).
The sensitivity of routine surveillance for detection of SSIs after THA was 56% (range, 33%-100%) (table 2). The criteria pertaining to hospital readmissions, including readmission within 365 days, antimicrobial receipt at readmission, and a readmission diagnosis code consistent with SSI, had higher sensitivities (all у79%) than those pertaining to the index hospital admission. The PPVs associated with the individual criteria were low, with the exception of a readmission diagnosis code suggestive of SSI (64%) (table 2). Combinations of screening criteria had higher sensitivities for detecting SSIs than did the individual criteria. Screening for the presence of an SSI diagnosis code for the index hospitalization or subsequent hospi- talization had substantially higher sensitivity than did routine surveillance (89%; range, 67%-100%) and had a PPV of 51% (range, 37%-67%). Including antimicrobial exposure of у7 days during the index hospitalization with SSI diagnosis codes increased the sensitivity to 93% (range, 87%-100%) but reduced the PPV to 25% (range, 19%-43%) (table 2) . Table 3 presents the prevalence of various screening criteria. Because most patients with SSI after THA required readmission to the hospital within a year after the procedure, limiting surveillance to the approximately one-fifth of individuals who were readmitted would detect 89% of SSIs. Alternatively, screening for patients with diagnosis codes for infection during the index hospitalization or subsequent hospitalization or screening for у7 days of antimicrobial exposure during the index hospitalization and/or diagnosis codes for infection would allow focused surveillance of an even smaller proportion (3.6% and 6.2%, respectively) of patients undergoing THA, with high sensitivity (89% and 93%, respectively) (table 2).
TKA. A total of 4194 TKA procedures were performed at the 5 participating medical centers during the study period (range, 573-1205 procedures per hospital). Routine surveillance identified 30 SSIs (0.72%), including 6 superficial incisional, 14 deep incisional, and 10 organ/space SSIs. Research personnel reviewed a random sample of 979 patients who were not previously known to have SSIs and found 11 additional SSIs, including 8 superficial incisional SSIs, 2 deep incisional SSIs, and 1 organ/space SSI. Extrapolating to the entire study population, the adjusted overall SSI rate was 1.83%.
As with THA, most SSIs after TKA were detected during a subsequent hospitalization. An antimicrobial exposure threshold of у7 days was also found to have the best combination of sensitivity and specificity for discriminating patients with SSIs and those without SSIs. The median time to hospital readmission was significantly shorter for patients with SSIs (median, 22.5 days; interquartile range, 57 days) than for patients without SSIs (median, 115.5 days; interquartile range, 170 days) (table 4).
The sensitivity of routine surveillance for detection of SSIs after TKA was 39% (range, 11%-100%) (table 2). As with THA, a diagnosis code for SSI during either the index hospitalization or a subsequent hospitalization was more sensitive than routine surveillance (81%; range, 64%-100%) and had a PPV of 55% (range, 21%-100%) (table 2). The addition of screening for antimicrobial exposure у7 days during the index hospitalization to SSI diagnosis codes improved sensitivity (86%; range, 64%-100%) at the cost of a decreased PPV (39%; range, 17%-100%) (table 2).
The prevalence of most screening criteria was similar in the population that underwent THA and the population that underwent TKA (table 3) . Screening for an ICD-9-CM diagnosis code suggestive of infection or the combination of antimicrobial exposure у7 days for the index hospitalization and/or an ICD-9-CM code that indicated SSI during the index hospitalization or a subsequent hospitalization would limit screening to 2.7% or 4.0%, respectively, of all patients undergoing TKA and would identify 81% or 86%, respectively, of the SSI cases. 
DISCUSSION
These results are consistent with the results of prior studies and suggest that screening for SSIs with use of diagnosis codes and a quantitative measurement of antimicrobial exposure can be a useful SSI surveillance strategy after orthopedic procedures. For both THA and TKA procedures, ICD-9-CM diagnosis code-based screening was substantially more sensitive than routine surveillance, with a reasonable PPV (figure 1). Addition of у7 days of antimicrobial exposure during the index hospitalization slightly improved sensitivity at the cost of lowering the PPV. We found diagnosis code-based screening to be more sensitive than routine surveillance for identification of the subset of SSIs classified as deep incisional or organ/space (sensitivities of 83% and 50%, respectively, for THA, and 86% and 65%, respectively, for TKA). This finding is important because of the controversial relevance of superficial incisional SSI surveillance [13] .
Antimicrobial exposure-based or diagnosis code-based screening identified some SSIs that were missed by routine surveillance. Adjusted SSI rates were approximately double the SSI rates determined by routine surveillance for both THA and TKA. One possible reason for this discrepancy is that, because routine surveillance is heavily dependent on microbiology culture data, it misses SSIs that meet the clinical rather than microbiological components of the NHSN SSI definition. In addition, the difficulty of sustaining labor-intensive conventional surveillance over time may lead to incomplete case ascertainment.
These algorithms improve standardization of surveillance through use of relatively objective data that are electronically accessible by many hospitals. This standardization could minimize variability in apparent SSI rates that reflect interinstitutional differences in personnel or other resources available for surveillance efforts rather than true differences in infection rates. This method also has the potential to increase the efficiency of SSI surveillance. On the basis of our results, we estimate that diagnosis-based screening could be used to focus medical record review on the ∼1 of 25 patients undergoing arthroplasty procedures who are most likely to have SSIs. Alternatively, diagnosis code-based screening alone could serve as an efficient surrogate for full SSI surveillance, and laborintensive confirmation of the SSI status of patients who meet screening criteria could be reserved for instances when the proportion of patients who meet diagnosis code criteria is higher than a specified threshold.
Because THA and TKA involve implantation of prosthetic material, the NHSN definitions require that surveillance for deep incisional and organ/space infections continue for 1 year after the operation. Our results confirmed that most SSIs after arthroplasty were diagnosed after the index hospitalization; in our study population, 185% of SSIs were identified during a subsequent hospitalization. Expanding the duration of diagnosis code-based screening to encompass all hospital readmissions within a year after the initial surgery identified SSIs that occurred after the initial inpatient stay. We also evaluated receipt of antimicrobial therapy during subsequent hospitalizations during the year after the surgical procedure but found that this criterion had poor predictive value, because patients had many indications for antimicrobial treatment during subsequent hospitalizations. Nearly all SSIs were diagnosed within Institutional surgical site infection (SSI) rates after total hip arthroplasty (A) and total knee arthroplasty (B) with use of different methods of surveillance. Diagonal bars represent the rates obtained using medical review as the gold standard, dotted bars represent the rates obtained by routine surveillance, and black bars represent the rates obtained using discharge diagnosis codes to screen for SSI, followed by medical record review for validation. Of the 8 participating institutions, 1 participated in both the total hip arthroplasty and total knee arthroplasty studies.
the 70 days after surgery. Although the NHSN requires that surveillance extend to a year after surgical procedures that involve implantations, according to our results, surveillance during the 70 days after arthroplasty will identify nearly all SSIs and may improve the feasibility of surveillance. Our method focused on inpatient SSI surveillance using information available in inpatient data systems and did not include SSIs detected solely in ambulatory settings. It is likely that SSIs detected in inpatient settings are more serious and are associated with higher morbidity rates and use of health care resources, compared with infections that do not require additional hospitalization. Huotari and Lyytikainen [14] reported that 70% of SSIs after orthopedic procedures that were detected during subsequent hospital stays were severe (either deep incisional or organ/space), whereas SSIs detected in outpatients were more likely to be superficial (86%). These methods also do not identify patients with SSIs who were readmitted to hospitals other than the hospital where the index surgery was performed. Other surveillance strategies that use automated data available from claims data submitted to insurers (e.g., Centers for Medicare and Medicaid Services) to identify patients with SSIs identified in ambulatory settings or during subsequent hospitalizations at other facilities show promising results [15] [16] [17] [18] [19] .
Although use of administrative data, such as diagnosis codes, is attractive because these data are relatively easy to access, it is important to acknowledge that use of these data has significant shortcomings. One of the primary shortcomings is the potential inaccuracy and subjectivity of coding data, which is influenced by the content and completeness of the information documented in the medical record [11] . Variability in the accuracy and thoroughness of diagnosis coding by individual hos-pitals could also affect the usefulness of such data for surveillance and interhospital comparisons. These factors may be magnified by anticipated changes to hospital reimbursement for certain health care-associated conditions, including some SSIs [1] , which may discourage coding of such conditions. We attempted to minimize some of these limitations by including a small number of diagnosis codes that were likely to be specific for SSI after arthroplasty. Pharmacy data may more accurately reflect the presence of an infection but are currently not electronically accessible for surveillance purposes in all hospitals. In addition, antimicrobial prescribing practices may vary over time, affecting the performance of pharmacy-based screening algorithms. Given these concerns, diagnosis code-based or antimicrobial exposure-based screening algorithms, if adopted, will need to be periodically reevaluated.
Our study has a number of limitations. First, we may have missed some infections or overestimated the number of infections because we did not review the medical records from all patients in our study populations. Second, although this was a multicenter study involving 8 hospitals, most participating sites were large academic medical centers, and our results may not be generalizable to all hospitals. Additional studies are needed to evaluate the usefulness of the enhanced SSI surveillance method in smaller, nonacademic centers or in resourcelimited settings.
SSI surveillance is an essential component of infection prevention efforts, but traditional surveillance methods are both resource intensive and subject to variability in case ascertainment. Our current and past studies demonstrate that screening based on diagnosis codes and inpatient pharmacy data can be used to identify SSIs after different types of commonly performed procedures, including some procedures targeted by the national Surgical Care Improvement Project. Diagnosis codebased screening identified infections after THA and TKA that were missed by traditional approaches and can be used to concentrate limited surveillance resources on patients who are most likely to have SSIs. Consideration should be given to incorporating this screening method into standard SSI surveillance for these surgical procedures.
